https://clinicaltrials.gov/ct2/show/NCT03119649?term=glpg&rank=44
ENROLLING | RESTORE CFTR FUNCTION
Phase 2a study of Galapagos GLPG2222 in adults with CF ›
DESCRIPTION: This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of GLPG2222 in adults with CF who have two copies of the F508del mutation.
AGE: 18 Years and Older
MUTATION: Two Copies F508del
FEV1% PREDICTED: 40% or greater
NUMBER OF VISITS: 5
LENGTH OF PARTICIPATION: 10 weeks
http://labiotech.eu/galapagos-cystic-fibrosis-glpg3067-phase-i/
ENROLLING | RESTORE CFTR FUNCTION
Phase 2a study of Galapagos GLPG2222 in adults with CF ›
DESCRIPTION: This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of GLPG2222 in adults with CF who have two copies of the F508del mutation.
AGE: 18 Years and Older
MUTATION: Two Copies F508del
FEV1% PREDICTED: 40% or greater
NUMBER OF VISITS: 5
LENGTH OF PARTICIPATION: 10 weeks
http://labiotech.eu/galapagos-cystic-fibrosis-glpg3067-phase-i/
Last edited: